Maureen Hillenmeyer is the founder of Hexagon Bio. Hexagon Bio has raised $323M in total funding. Latest round: Series B. Based in Menlo Park, California.
Maureen Hillenmeyer, PhD, is the Co-founder and CEO of Hexagon Bio, a biopharmaceutical company focused on pioneering drug discovery from the global metagenome to address oncology and infectious diseases. She co-founded Hexagon Bio in 2017 after generating preliminary data at Stanford that attracted venture capital.
Full founder directory · Investor directory · Company funding database · Fundraising library